These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24650995)

  • 1. Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients.
    Sagnelli C; Uberti-Foppa C; Galli L; Pasquale G; Coppola N; Albarello L; Doglioni C; Lazzarin A; Sagnelli E
    Braz J Infect Dis; 2014; 18(2):164-9. PubMed ID: 24650995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus.
    Macías J; Berenguer J; Japón MA; Girón JA; Rivero A; López-Cortés LF; Moreno A; González-Serrano M; Iribarren JA; Ortega E; Miralles P; Mira JA; Pineda JA
    Hepatology; 2009 Oct; 50(4):1056-63. PubMed ID: 19670415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [ANRS HC 02 RIBAVIC: histo-pathological impact].
    Pol S
    Gastroenterol Clin Biol; 2009 Mar; 33 Suppl 2():S106-9. PubMed ID: 19375037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
    Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
    HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic issues in HIV/HCV-coinfected patients.
    Sulkowski MS; Benhamou Y
    J Viral Hepat; 2007 Jun; 14(6):371-86. PubMed ID: 17501757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of unsuccessful treatment with peginterferon and ribavirin on the liver fibrosis course of HIV/HCV-coinfected patients.
    Collazos J; Asensi V; de la Fuente B; Cartón JA
    Curr HIV Res; 2012 Dec; 10(8):679-87. PubMed ID: 23061599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C).
    Sherman KE; Andersen JW; Butt AA; Umbleja T; Alston B; Koziel MJ; Peters MG; Sulkowski M; Goodman ZD; Chung RT;
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):597-605. PubMed ID: 20921898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients.
    Macías J; Berenguer J; Japón MA; Girón-González JA; Rivero A; López-Cortés LF; Moreno A; Márquez M; Iribarren JA; Ortega E; Miralles P; Merchante N; Pineda JA
    Hepatology; 2012 Oct; 56(4):1261-70. PubMed ID: 22508322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era.
    Sanmartin R; de Felipe E; Tor J; Sanvicens A; Barluenga E; Martinez E; Muga R; Jou A; Ojanguren I; López JJ; Clotet B; Tural C
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1235-43. PubMed ID: 22443303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of hepatitis C virus coinfection in HIV-infected persons.
    O'Leary JG; Chung RT
    AIDS Read; 2006 Jun; 16(6):313-6, 318-20. PubMed ID: 16795921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; Marxuach-Cuétara AM; López-Torres A; Jiménez-Rivera J
    J Hepatol; 2007 Apr; 46(4):613-9. PubMed ID: 17316873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.
    Berenguer J; Bellón JM; Miralles P; Alvarez E; Castillo I; Cosín J; López JC; Sánchez Conde M; Padilla B; Resino S
    Clin Infect Dis; 2008 Jan; 46(1):137-43. PubMed ID: 18171229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
    Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
    Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C.
    Labarga P; Fernández-Montero JV; de Mendoza C; Barreiro P; Soriano V
    Antivir Ther; 2015; 20(1):65-72. PubMed ID: 25105286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrosis Progression in Paired Liver Biopsies from HIV/HCV-Coinfected Patients without Prior Treatment of Hepatitis C.
    Leite AG; Duarte MI; Mendes-Correa MC
    J Int Assoc Provid AIDS Care; 2015; 14(5):463-8. PubMed ID: 26056147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs.
    Konerman MA; Mehta SH; Sutcliffe CG; Vu T; Higgins Y; Torbenson MS; Moore RD; Thomas DL; Sulkowski MS
    Hepatology; 2014 Mar; 59(3):767-75. PubMed ID: 24436062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
    Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
    PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver fibrosis progression in HIV/hepatitis C virus coinfected patients with normal aminotransferases levels.
    Pace FH; Ferreira LE; Silva AE; Ferraz ML
    Rev Soc Bras Med Trop; 2012; 45(4):444-7. PubMed ID: 22930041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.
    Benhamou Y; Di Martino V; Bochet M; Colombet G; Thibault V; Liou A; Katlama C; Poynard T;
    Hepatology; 2001 Aug; 34(2):283-7. PubMed ID: 11481613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon.
    McGovern BH; Birch C; Zaman MT; Bica I; Stone D; Quirk JR; Davis B; Zachary K; Basgoz N; Graeme-Cook F; Gandhi RT
    Clin Infect Dis; 2007 Nov; 45(10):1386-92. PubMed ID: 17968840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.